Shots:
- Exelixis has exercised its exclusive option under the companies’ July 2019 agreement to in-license XL114 (formerly AUR104), following the US FDA’s IND acceptance for P-I study in NHL
- Exelixis has assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114. By exercising the option for XL114, Aurigene received $10M as option exercise payment
- Exelixis previously exercised its option to in-license XL102 from Aurigene in Dec 2020 and initiated a P-I trial of XL102 as a single agent and in combination with other anti-cancer agents in patients with advanced or metastatic solid tumors in Jan 2021
Click here to read the full press release/ article | Ref: Businesswire | Image: Twitter
The post Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA’s Acceptance of IND for P-I Study of XL114 in Non-Hodgkin’s Lymphoma first appeared on PharmaShots.
